Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Intermediate-risk neuroblastoma
Data

Cancers·Intermediate-risk neuroblastoma

DataIntermediate-risk neuroblastoma

Back to the Intermediate-risk neuroblastoma hub →31 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

31

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
Single-system Langerhans cell histiocytosis (bone, skin or one other organ)
Shares Late effects and survivorship toxicity, MRI, Cytotoxic chemotherapy and the tags subtype-page, paediatric.
Cancer
Acute myeloid leukaemia in children
Shares Late effects and survivorship toxicity, Cardio-oncology, Children's Oncology Group (COG), Etoposide and the tags subtype-page, paediatric.
Cancer
Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)
Shares Late effects and survivorship toxicity, MRI, Cytotoxic chemotherapy and the tags subtype-page, paediatric.
Cancer
Standard-risk B-cell acute lymphoblastic leukaemia in children
Shares Children's Oncology Group (COG), Cyclophosphamide, Doxorubicin and the tags subtype-page, paediatric.
Cancer
High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)
Shares Children's Oncology Group (COG), Cyclophosphamide, Doxorubicin, Cytotoxic chemotherapy and the tags subtype-page, paediatric.
Cancer
Relapsed and refractory acute lymphoblastic leukaemia in children
Shares Children's Oncology Group (COG), Etoposide, Cyclophosphamide and the tags subtype-page, paediatric.
Cancer
Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)
Shares Children's Oncology Group (COG) and the tags subtype-page, paediatric.
Cancer
Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)
Shares Children's Oncology Group (COG) and the tags subtype-page, paediatric.

technologies

11

Allogeneic stem cell transplantation Autologous stem cell transplant (high-dose therapy)CAR-T cell therapy Cardio-oncology Cytotoxic chemotherapy IMRT / IGRT (modern external beam)MIBG imaging and 131I-MIBG therapy MRI Oncofertility and fertility preservation Platinum agents Topoisomerase-I inhibitors (and ADC payloads)

targets

1

KMT2A (MLL) rearrangement

drugs

4

ApprovedCytotoxic chemotherapy (platinum)

ApprovedAlkylating agent (oxazaphosphorine prodrug)

Cyclophosphamide · Cytoxan / Endoxan

ApprovedCytotoxic chemotherapy (anthracycline)

Doxorubicin · Adriamycin

ApprovedTopoisomerase II inhibitor (podophyllotoxin derivative)

Etoposide · VePesid / Etopophos / Toposar

companies

1

Bristol Myers Squibb

institutions

2

Children's Oncology Group (COG)SIOP Europe (European Society for Paediatric Oncology)

terms

6

INRG staging and risk groups Late effects and survivorship toxicity MYCN amplification Radiotherapy Segmental chromosomal aberrations and ploidy (neuroblastoma)Urinary catecholamine metabolites (VMA and HVA)

trials

1

ideas

1

18F-MFBG PET replacing 123I-MIBG scintigraphy

key papers

3

A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma The International Neuroblastoma Risk Group (INRG) classification system

biomarkers

1

MYCN amplification

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Add key papers to 147 cancer subtype pages · diff · file

Wikipedia

Sources & links

Wikipedia: Neuroblastoma
NCI PDQ: Neuroblastoma Treatment

subtype-page paediatric

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Intermediate-risk neuroblastoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/neuroblastoma-intermediate-risk/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id neuroblastoma-intermediate-risk.

WebMCP tools registered on this page: onco_search, onco_get_entity.